363 related articles for article (PubMed ID: 30130293)
21. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
22. Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women.
Tersigni C; Di Simone N; Tempestilli E; Cianfrini F; Russo R; Moruzzi MC; Amar ID; Fiorelli A; Scambia G; Villa P
J Obstet Gynaecol; 2015; 35(8):835-8. PubMed ID: 25968636
[TBL] [Abstract][Full Text] [Related]
23. Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey.
Richter LA; Han J; Bradley S; Lynce FC; Willey SC; Tefera E; Pollack CE
Menopause; 2019 Jul; 26(7):714-719. PubMed ID: 30939535
[TBL] [Abstract][Full Text] [Related]
24. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
[TBL] [Abstract][Full Text] [Related]
25. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs.
Nappi RE; Palacios S; Particco M; Panay N
Maturitas; 2016 Sep; 91():81-90. PubMed ID: 27451325
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
Wang J; Wang L
Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
[TBL] [Abstract][Full Text] [Related]
27. Iranian postmenopausal women's experiences of treatment of symptomatic vulvovaginal atrophy.
Fooladi E; Deldar M; Mohammadzadeh F; Ahmadnia E; Khani S; Ghanbari Z
Climacteric; 2017 Feb; 20(1):67-71. PubMed ID: 28064523
[TBL] [Abstract][Full Text] [Related]
28. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
29. Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: findings from the REVIVE survey.
Freedman MA
Womens Health (Lond); 2014 Jul; 10(4):445-54. PubMed ID: 25259904
[TBL] [Abstract][Full Text] [Related]
30. Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
Mattsson LÅ; Ericsson Å; Bøgelund M; Maamari R
Maturitas; 2013 Mar; 74(3):259-63. PubMed ID: 23312488
[TBL] [Abstract][Full Text] [Related]
31. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
[TBL] [Abstract][Full Text] [Related]
32. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
[TBL] [Abstract][Full Text] [Related]
33. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
Constantine G; Millheiser LS; Kaunitz AM; Parish SJ; Graham S; Bernick B; Mirkin S
Menopause; 2019 Nov; 26(11):1259-1264. PubMed ID: 31688572
[TBL] [Abstract][Full Text] [Related]
34. Personal opinion: Treatment of vulvovaginal atrophy--are hidden interests and misinformation preventing better management?
Pines A; Sturdee DW
Climacteric; 2015; 18(6):802-4. PubMed ID: 26397968
[TBL] [Abstract][Full Text] [Related]
35. Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Pagano T; De Rosa P; Vallone R; Schettini F; Arpino G; De Placido S; Nazzaro G; Locci M; De Placido G
Menopause; 2016 Oct; 23(10):1108-13. PubMed ID: 27648595
[TBL] [Abstract][Full Text] [Related]
36. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
Vicariotto F; Raichi M
Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
[TBL] [Abstract][Full Text] [Related]
37. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women.
Nappi RE; Kotek M; Brešt'anský A; Giordan N; Tramentozzi E
Climacteric; 2020 Oct; 23(5):519-524. PubMed ID: 32396754
[No Abstract] [Full Text] [Related]
39. Managing postmenopausal vaginal atrophy. Vaginal dryness is one of the most irritating symptoms of menopause. Here are some ways to relieve it.
Harv Womens Health Watch; 2010 Mar; 17(7):4-5. PubMed ID: 20480969
[No Abstract] [Full Text] [Related]
40. A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.
Simon JA; Archer DF; Constantine GD; Pickar JH; Amadio JM; Bernick B; Graham S; Mirkin S
Maturitas; 2017 May; 99():51-58. PubMed ID: 28364869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]